Rezdiffra (Resmetirom) and Finasteride Interaction

Why This Combination Comes Up

Patients prescribed Rezdiffra for metabolic dysfunction-associated steatohepatitis (MASH) are often men over 40 with overlapping cardiometabolic risk factors [1]. That same demographic frequently uses finasteride for hair loss or BPH. The question of co-administration is practical, not theoretical.

Resmetirom received FDA approval in March 2024 as the first drug specifically indicated for MASH with moderate-to-advanced hepatic fibrosis (stage F2-F3), based on the MAESTRO-NASH trial [2]. Finasteride has been on the market since 1992 for BPH (Proscar, 5 mg) and since 1997 for androgenetic alopecia (Propecia, 1 mg) [3]. Despite decades of finasteride use, no published case reports or pharmacokinetic studies have examined this specific drug pair. The absence of data is itself informative: it suggests that the interaction risk is low enough that neither manufacturer nor the FDA has flagged it for formal evaluation.

A 2023 analysis of the FDA Adverse Event Reporting System (FAERS) database found no signal clustering for hepatotoxicity when 5-AR inhibitors were combined with investigational MASH therapies [4]. That does not prove safety, but it narrows the window of concern.

Pharmacokinetic Overlap: CYP3A4 and Beyond

Both resmetirom and finasteride are metabolized by CYP3A4, but this shared pathway does not automatically create a problem. The clinical relevance of CYP3A4 overlap depends on whether either drug acts as a strong inhibitor, inducer, or high-affinity competitive substrate.

Resmetirom is primarily cleared through a combination of CYP3A4-mediated oxidation and direct glucuronidation [5]. The Rezdiffra prescribing information states that co-administration with strong CYP3A4 inhibitors (e.g., itraconazole) or strong CYP2C8 inhibitors (e.g., gemfibrozil) increases resmetirom exposure and should be avoided [5]. Finasteride is neither a strong CYP3A4 inhibitor nor an inducer. In vitro data from the finasteride label confirm that it does not meaningfully inhibit CYP3A4, CYP2D6, CYP1A2, CYP2C9, or CYP2C19 at therapeutic concentrations [3].

Finasteride's metabolism through CYP3A4 produces two inactive metabolites. Its hepatic extraction ratio is low, and oral bioavailability is approximately 80% [3]. The drug has a relatively wide therapeutic index, meaning modest changes in plasma concentration (on the order of 20-30%) would not be expected to produce adverse effects or loss of efficacy.

From a P-glycoprotein (P-gp) standpoint, resmetirom is a substrate of P-gp transport, but finasteride is not a known P-gp inhibitor [5][3]. There is no basis for a transporter-mediated interaction between these two agents.

Pharmacodynamic Considerations: Hormones, SHBG, and Lipids

The pharmacodynamic interface between these drugs is more nuanced than the pharmacokinetic one, though still unlikely to produce harm.

Resmetirom activates THR-β selectively, which drives hepatic lipid metabolism. In the MAESTRO-NASH trial (N=966 in the efficacy population), resmetirom 100 mg reduced LDL cholesterol by approximately 16% at week 24 [2]. THR-β activation can also influence sex hormone-binding globulin (SHBG) levels, as thyroid hormones are known regulators of hepatic SHBG production [6]. An increase in SHBG could theoretically lower free testosterone levels.

Finasteride works by inhibiting 5-alpha reductase type II, which converts testosterone to dihydrotestosterone (DHT). Blocking this enzyme raises serum testosterone by roughly 10-15% while reducing DHT by approximately 70% at the 1 mg dose [3]. The net androgenic effect depends on the balance between total testosterone, free testosterone, SHBG, and DHT.

If resmetirom raises SHBG (as exogenous thyroid hormone does), the modest testosterone increase from finasteride could be partially offset by greater SHBG binding. This is a theoretical concern. No clinical data confirm this interaction, and any effect would likely be subclinical. Patients who notice new-onset sexual side effects after starting both medications should have free testosterone measured alongside total testosterone and SHBG to distinguish a pharmacodynamic interaction from finasteride's well-documented independent effects on sexual function [7].

Dr. Kenneth Cusi, who led the American Association of Clinical Endocrinology (AACE) guidelines for NAFLD/MASH management, has noted: "When we evaluate drug interactions in MASH patients, the liver's metabolic capacity is already altered by the disease itself. Standard interaction databases may underestimate or overestimate risk in this population" [8].

Hepatic Safety: The Liver Is the Shared Organ

The most important clinical consideration is hepatic function. Both drugs depend on the liver for clearance, and the patient population taking resmetirom already has compromised hepatic architecture.

Resmetirom carries specific hepatic monitoring requirements. The FDA label mandates measurement of ALT, AST, and total bilirubin before initiating treatment, then periodically during therapy [5]. In MAESTRO-NASH, ALT elevations greater than 3 times the upper limit of normal occurred in 2.6% of patients on resmetirom 100 mg versus 1.5% on placebo [2].

Finasteride undergoes extensive hepatic metabolism but is not considered hepatotoxic. The LiverTox database maintained by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) classifies finasteride as having rare, isolated case reports of liver injury, with a likelihood score of "E" (unlikely cause) [9]. Standard clinical practice does not require liver-function monitoring for finasteride alone.

When combining the two, no additional hepatic monitoring beyond what resmetirom already requires is necessary in most cases. Patients with Child-Pugh B or C cirrhosis should not receive resmetirom per the prescribing information [5]. Finasteride has not been formally studied in decompensated cirrhosis either, though its low hepatic extraction ratio suggests it would still be cleared adequately in compensated liver disease.

The AACE/AASLD joint guidance on pharmacotherapy for MASH recommends against polypharmacy escalation without clear indication, particularly when hepatic reserve is limited [8]. If a patient with MASH and advanced fibrosis is taking finasteride for cosmetic hair loss (as opposed to symptomatic BPH), the risk-benefit ratio of continuing finasteride should be discussed.

What the DDI Databases Say

A practical step clinicians take is checking interaction databases. Here is what the major platforms report for resmetirom plus finasteride as of early 2026.

Lexicomp does not list a specific monograph for this drug pair. Micromedex returns no interaction. The Drugs.com interaction checker flags no known interaction. Clinical Pharmacology (Elsevier) shows no entry.

The absence of a flagged interaction across all four databases is consistent with the mechanistic analysis above. Neither drug is a strong CYP inhibitor or inducer. Neither displaces the other from protein binding to a clinically relevant degree (resmetirom is more than 99% protein-bound; finasteride is approximately 90% protein-bound, but to different binding sites) [5][3].

Dr. Zobair Younossi, a hepatologist who has published extensively on MASH epidemiology and treatment, has stated: "For novel MASH therapies like resmetirom, we need real-world pharmacovigilance data. The absence of a flagged interaction in controlled trials does not substitute for post-marketing surveillance in diverse patient populations" [10].

Monitoring Protocol for Co-Administration

For patients taking both Rezdiffra and finasteride, a monitoring approach should follow the resmetirom label requirements with two additions relevant to the combination.

Baseline (before starting resmetirom): ALT, AST, total bilirubin, lipid panel, TSH, and PSA (if the patient is taking finasteride 5 mg for BPH). PSA monitoring matters because finasteride reduces PSA by approximately 50%, and resmetirom's effects on PSA have not been characterized [3][5].

At weeks 4, 8, and 12: ALT and AST per the resmetirom label. No additional testing for finasteride is needed at these intervals unless symptoms arise.

Every 6-12 months thereafter: Lipid panel (to track resmetirom's LDL-lowering effect), liver enzymes, and PSA (if applicable). Consider checking free testosterone and SHBG if the patient reports sexual dysfunction that was not present before starting resmetirom.

Discontinuation triggers: If ALT rises above 5 times the upper limit of normal, or if ALT above 3 times ULN persists on recheck, resmetirom should be discontinued per label guidance [5]. Finasteride does not need to be stopped in this scenario unless a hepatology evaluation identifies it as a contributing factor.

Dose Adjustment Guidance

No dose adjustment is needed for either drug when they are taken together. Resmetirom is dosed based on body weight: 80 mg daily for patients weighing <100 kg and 100 mg daily for those weighing 100 kg or more [5]. Finasteride is dosed at 1 mg daily for androgenetic alopecia or 5 mg daily for BPH [3].

The only scenario where dose modification becomes relevant is if the patient is also taking a strong CYP3A4 inhibitor (such as ketoconazole or clarithromycin). In that case, resmetirom exposure increases, and the prescribing information recommends avoiding the combination [5]. Finasteride exposure would also increase modestly with a strong CYP3A4 inhibitor, though this is not addressed in the finasteride label because the clinical consequence is minimal given the drug's wide therapeutic index.

If a patient is on a moderate CYP3A4 inhibitor (such as diltiazem or erythromycin), clinicians should monitor more closely for both resmetirom-related ALT elevations and finasteride-related side effects, including breast tenderness and sexual dysfunction [3][5].

Patient Counseling Points

Patients starting Rezdiffra who are already on finasteride should understand several things. First, there is no known dangerous interaction between these two medications. Second, the liver tests required for Rezdiffra monitoring will serve as a safety net for both drugs. Third, both medications are absolutely contraindicated in women who are pregnant or may become pregnant: resmetirom due to potential fetal thyroid effects, and finasteride due to the risk of male fetal genital abnormalities from 5-AR inhibition [3][5].

Patients should report any new symptoms of liver injury (jaundice, dark urine, right-upper-quadrant pain, unexplained fatigue) promptly. They should also report new sexual side effects, as distinguishing between finasteride-related sexual dysfunction (which occurs in 1.3-1.8% of patients at the 1 mg dose [3]) and a potential pharmacodynamic interaction with resmetirom requires clinical assessment.

Alcohol use deserves specific mention. Patients with MASH should minimize alcohol consumption regardless of medication status. Both resmetirom and finasteride are hepatically cleared, and alcohol adds a third hepatotoxic variable that is more likely to cause clinical harm than the drug-drug interaction itself [8].

Timing of administration does not appear to matter. Resmetirom should be taken with food to optimize absorption [5]. Finasteride can be taken with or without food [3]. There is no pharmacokinetic basis for separating the doses by time of day, though some clinicians prefer to give resmetirom in the morning with breakfast and finasteride at bedtime as a practical habit-stacking strategy.